Source: https://www.breyanzi.com/lbcl/aboutThe US Food and Drug Administration on Thursday expanded the use of Bristol Myers Squibb’s cell therapy, Breyanzi, for a type of slow-growing blood cancer, marking the second approval for the treatment.Breyanzi was initially approved in the United States in June 2022 to treat a